Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma

References

• Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848–857.
   PubMed Web of Science ®Google Scholar
• Park HJ, Park EH, Jung KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol. 2012;47:28–38.
   PubMedGoogle Scholar
• Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–834.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Remstein ED, Ansell SM, et al. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006;47:1794–1799.
   PubMed Web of Science ®Google Scholar
• Rossi G, Donisi A, Casari S, et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999;86:2391–2397.
   PubMed Web of Science ®Google Scholar
• Gora-Tybor J, Szemraj J, Robak T, et al. Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. Blood Cells Mol Dis. 2015;54:139–143.
   PubMed Web of Science ®Google Scholar
• Kim DH, Lee NY, Lee MH, et al. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol. 2008;140:71–79.
   PubMed Web of Science ®Google Scholar
• Grunewald FS, Prota AE, Giese A, et al. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta. 2010;1804:567–580.
   PubMed Web of Science ®Google Scholar
• Jia H, Bagherzadeh A, Bicknell R, et al. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem. 2004;279:36148–36157.
   PubMed Web of Science ®Google Scholar
• Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915–922.
   PubMed Web of Science ®Google Scholar
• Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381–1390.
   PubMed Web of Science ®Google Scholar
• Prior SJ, Hagberg JM, Paton CM, et al. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol. 2006;290:H1848–H1855.
   PubMed Web of Science ®Google Scholar
• Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37:93–99.
   PubMed Web of Science ®Google Scholar
• Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443–448.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–1235.
   PubMed Web of Science ®Google Scholar
• Xu B, Li JM, Tong N, et al. VEGFA +936C > T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet. 2010;198:7–14.
   PubMed Web of Science ®Google Scholar
• Song GG, Kim JH, Lee YH. Vascular endothelial growth factor gene polymorphisms and vasculitis susceptibility: a meta-analysis. Hum Immunol. 2014;75:541–548.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li S, Xiao HQ, et al. Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: a systematic review and meta-analysis. Oncol Lett. 2013;6:1068–1078.
   PubMed Web of Science ®Google Scholar
• Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007;46:446–455.
   PubMed Web of Science ®Google Scholar
• Kim MK, Suh C, Chi HS, et al. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci. 2012;103:497–503.
   PubMed Web of Science ®Google Scholar
• Buroker NE, Ning XH, Zhou ZN, et al. VEGFA SNPs and transcriptional factor binding sites associated with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau. J Physiol Sci. 2013;63:183–193.
   PubMed Web of Science ®Google Scholar
• Buroker NE. SNP (rs1570360) in transcriptional factor binding sites of the VEGFA promoter is associated with hypertensive nephropathy and diabetic retinopathy. BJMMR. 2015;10:1–11.
   Google Scholar
• Chen N, Ma CN, Zhao M, et al. Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer. Genet Mol Res. 2015;14:16006–16011.
   PubMed Web of Science ®Google Scholar
• Wang L, Ji S, Cheng Z. Association between polymorphisms in vascular endothelial growth factor gene and response to chemotherapies in colorectal cancer: a meta-analysis. PLoS One. 2015;10:e0126619.
   PubMed Web of Science ®Google Scholar
• Hein A, Lambrechts D, von Minckwitz G, et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: results from the randomized phase III GeparQuinto study. Int J Cancer. 2015;137:2981–2988.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135:1247–1256.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Nurmi H, Holte H, et al. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. Eur J Haematol. 2012;89:395–402.
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167–3172.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrom M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117:109–116.
   PubMed Web of Science ®Google Scholar